Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| Finite Lived Intangible Assets [Line Items] | |||
| Net Carrying Amount | $ 11,962,000 | $ 13,663,000 | |
| Amortization expense | 1,700,000 | 1,700,000 | $ 1,700,000 |
| Novartis | |||
| Finite Lived Intangible Assets [Line Items] | |||
| Gross Carrying Amount | 24,857,000 | 24,857,000 | |
| Accumulated Amortization | 12,895,000 | 11,194,000 | |
| Impairment | 0 | 0 | |
| Net Carrying Amount | 11,962,000 | 13,663,000 | |
| Novartis | Patents | |||
| Finite Lived Intangible Assets [Line Items] | |||
| Gross Carrying Amount | 21,728,000 | 21,728,000 | |
| Accumulated Amortization | 11,770,000 | 10,217,000 | |
| Impairment | 0 | 0 | |
| Net Carrying Amount | $ 9,958,000 | $ 11,511,000 | |
| Useful Lives | 14 years | 14 years | |
| Novartis | License | |||
| Finite Lived Intangible Assets [Line Items] | |||
| Gross Carrying Amount | $ 3,129,000 | $ 3,129,000 | |
| Accumulated Amortization | 1,125,000 | 977,000 | |
| Impairment | 0 | 0 | |
| Net Carrying Amount | $ 2,004,000 | $ 2,152,000 | |
| Useful Lives | 21 years | 21 years | |